ATRIUM THERAPEUTICS INC
RNANASDAQTrading Snapshot
- Day Range
- $8.29 – $8.51
- 52-Week Range
- $8.10 – $73.06
- Volume
- $5.71B
- Avg Volume
- $4.84B
- Shares Outstanding
- 17.1M
- Next Earnings
- Nov 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $19M
- Last Q Revenue
- $3M
- P/E Ratio
- —
- P/S Ratio
- 3.4x
- EPS (TTM)
- $-5.04
- Dividend Yield
- —
Why Investors Own RNA
- ✓High-growth profile — revenue up +28.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ATRIUM THERAPEUTICS INC
RNA
StockOtter · stockotter.spaceAbout ATRIUM THERAPEUTICS INC
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on September 20, 2026 under the Company's 2026 Employment Inducement Incentiv
Avidity Biosciences (NASDAQ:RNA) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report)'s share price crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $15.18 and traded as low as $10.34.
Atrium Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it w
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13,
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, toda
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment befo